Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention

被引:43
|
作者
Nipp, Ryan D. [1 ]
Lee, Hang [2 ]
Gorton, Emily [1 ]
Lichtenstein, Morgan [1 ]
Kuchukhidze, Salome [1 ]
Park, Elyse [3 ,4 ]
Chabner, Bruce A. [1 ]
Moy, Beverly [1 ]
机构
[1] Massachusetts Gen Hosp, Canc Ctr, Div Hematol, Dept Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Canc Ctr, Biostat Ctr, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Psychiat, Biostat Ctr, Boston, MA 02114 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
来源
ONCOLOGIST | 2019年 / 24卷 / 08期
关键词
Health care costs; Cancer; Financial support; Financial insolvency; Clinical trial; Health care disparities; QUALITY-OF-LIFE; CARE; COST; TOXICITY; BARRIERS; IMPACT; EXPERIENCE; ENROLLMENT; RISK; LUNG;
D O I
10.1634/theoncologist.2019-0146
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The financial burden experienced by patients with cancer represents a barrier to clinical trial participation, and interventions targeting patients' financial concerns are needed. We sought to assess the impact of an equity intervention on clinical trial patients' financial burden. Materials and Methods We developed an equity intervention to reimburse nonclinical expenses related to trials (e.g., travel and lodging). From July 2015 to July 2017, we surveyed intervention and comparison patients matched by age, sex, cancer type, specific trial, and trial phase. We longitudinally assessed financial burden (e.g., trial-related travel and lodging cost concerns, financial wellbeing [FWB] with the COmprehensive Score for financial Toxicity [COST] measure) at baseline, day 45, and day 90. We used longitudinal models to assess intervention effects over time. Results Among 260 participants, intervention patients were more likely than comparison patients to have incomes under $60,000 (52% vs. 24%, p < .001) and to report travel-related (41.0% vs. 6.8%, p < 0.001) and lodging-related (32.5% vs. 2.0%, p < .001) cost concerns at baseline. Intervention patients were more likely to report travel to appointments as their most significant financial concern (24.0% vs. 7.0%, p = .001), and they had worse FWB than comparison patients (COST score: 15.32 vs. 23.88, p < .001). Over time, intervention patients experienced greater improvements in their travel-related (-10.0% vs. +1.2%, p = .010) and lodging-related (-3.9% vs. +4.0%, p = .003) cost concerns. Improvements in patients reporting travel to appointments as their most significant financial concern and COST scores were not statistically significant. Conclusion Cancer clinical trial participants may experience substantial financial issues, and this equity intervention demonstrates encouraging results for addressing these patients' longitudinal financial burden. Implications for Practice Clinical trials are critical for developing novel therapies for patients with cancer, yet financial barriers may discourage some patients from participating in cancer clinical trials. This study found that patients who received financial assistance from an equity intervention experienced significant improvements over time in their concerns about the cost of travel and lodging associated with clinical trials compared with comparison patients who did not receive financial assistance from the equity intervention. Among cancer clinical trial participants, an equity intervention shows potential for addressing patients' concerns regarding clinical trial-related travel and lodging expenses.
引用
收藏
页码:1048 / 1055
页数:8
相关论文
共 50 条
  • [1] Addressing financial concerns of cancer clinical trial participants: Longitudinal outcomes of an equity intervention.
    Nipp, Ryan David
    Lee, Hang
    Gorton, Emily
    Lichtenstein, Morgan
    Park, Elyse R.
    Chabner, Bruce Allan
    Moy, Beverly
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program
    Nipp, Ryan D.
    Lee, Hang
    Powell, Elizabeth
    Birrer, Nicole E.
    Poles, Emily
    Finkelstein, Daniel
    Winkfield, Karen
    Percac-Lima, Sanja
    Chabner, Bruce
    Moy, Beverly
    [J]. ONCOLOGIST, 2016, 21 (04): : 467 - 474
  • [3] Financial burden of cancer clinical trials: Impact of an equity program intervention
    Nipp, Ryan David
    Finkelstein, Daniel
    Powell, Elizabeth
    Vittorio, Lisa
    Birrer, Nicole
    Chabner, Bruce Allan
    Lee, Hang
    Moy, Beverly
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Prospective study of the financial burden of cancer clinical trial patients referred to a cancer care equity program (CCEP)
    Poles, Emily
    Nipp, Ryan David
    Park, Elyse R.
    Chabner, Bruce Allan
    Moy, Beverly
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Understanding the financial cost of cancer clinical trial participation
    Williams, Courtney P.
    Deng, Luqin
    Caston, Nicole E.
    Gallagher, Kathleen
    Angove, Rebekah
    Pisu, Maria
    Azuero, Andres
    Arend, Rebecca
    Rocque, Gabrielle B.
    [J]. CANCER MEDICINE, 2024, 13 (08):
  • [6] Educational intervention for providers addressing the diversity gap in cervical cancer clinical study participation
    Govender, Sarah-Leigh
    Mathias, Melissa
    Fury, Matthew
    Flink, Dina
    Yoo, Suk-Young
    Coates, Ebony
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 166 : S282 - S282
  • [7] Addressing financial toxicity in cancer clinical trial participation: Barriers and facilitators of enrolling in a reimbursement program for out-of-pocket travel costs
    Ramos, Elizabeth
    Nguyen, Vivian
    Santaniello, Ashley
    Dornsife, Dana
    Johnson, Robert G.
    Wileyto, Paul E.
    Vonderheide, Robert H.
    Guerra, Carmen E.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [8] BENEFITS AND BURDENS OF PARTICIPATION IN A LONGITUDINAL CLINICAL TRIAL
    Lazovski, Jaime
    Losso, Marcelo
    Krohmal, Benjamin
    Emanuel, Ezekiel J.
    Grady, Christine
    Wendler, David
    [J]. JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2009, 4 (03) : 89 - 97
  • [9] Development and Preliminary Testing of the Perceived Benefit and Burden Scales for Cancer Clinical Trial Participation
    Ulrich, Connie M.
    Zhou, Qiuping
    Ratcliffe, Sarah J.
    Knafl, Kathleen
    Wallen, Gwenyth R.
    Richmond, Therese S.
    Grady, Christine
    [J]. JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2018, 13 (03) : 230 - 238
  • [10] Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data
    Alpert, Ash B.
    Brewer, Jamie Renee
    Adams, Spencer
    Rivers, Lexis
    Orta, Sunshine
    Blosnich, John R.
    Miedlich, Susanne
    Kamen, Charles
    Dizon, Don S.
    Pazdur, Richard
    Beaver, Julia A.
    Fashoyin-Aje, Lola
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1825 - +